Latest
What’s new in the science of healthier aging.
Fifty-five source-reviewed articles cover everyday foundations, medicines and supplements, experimental biotechnology, aging measurements, and health and function. Each card shows what kind of evidence the story actually examines.
No stories match those choices—yet.
Clear the filters, browse a topic, or use a guided path. A zero result is not evidence that a topic has no research.
Everyday foundations
Stopping smoking was associated with lower mortality at every age studied
Two large observational analyses found substantially higher mortality with current cigarette smoking and lower excess mortality after stopping. The estimates describe populations; they do not promise a particular person extra years.
Human mortality · large observational cohortsRead the story
Health & function
STRIDE did not significantly reduce serious fall injuries in primary care
In 5,451 older adults at increased fall-injury risk, a nurse-led multifactorial strategy did not significantly reduce the first adjudicated serious fall injury versus enhanced usual care. A secondary self-reported fall-injury outcome differed.
Human serious fall injuries · large pragmatic cluster-randomized trialRead the story
Health & function
LiFE reduced self-reported falls by embedding activity in daily routines
Among 317 selected older adults at high risk of falls, the LiFE program integrated balance and strength activities into everyday routines and reduced the self-reported fall rate versus sham gentle exercise over 12 months.
Human self-reported falls and function · small randomized trialRead the story
Health & function
A tailored Tai Ji Quan program reduced falls in one high-risk trial
In 670 selected community-dwelling older adults at high risk of falling, a therapeutically tailored Tai Ji Quan program reduced falls over 24 weeks versus stretching and multimodal exercise.
Human fall incidence · three-arm randomized trialRead the story
Everyday foundations
DPP prevention effects persisted for 15 years—without an overall microvascular difference
Among adults at high risk for type 2 diabetes, the DPP lifestyle and metformin groups still had lower cumulative diabetes incidence after 15 years. The randomized groups did not differ significantly in the study’s aggregate microvascular outcome.
Human diabetes incidence and microvascular outcomes · long randomized follow-upRead the story
Everyday foundations
Look AHEAD improved weight and risk factors—not cardiovascular event rates
In 5,145 adults with type 2 diabetes and overweight or obesity, intensive lifestyle intervention produced greater sustained weight loss and improved several risk factors. It did not significantly reduce the trial’s primary cardiovascular outcome.
Human cardiovascular events and function · large randomized trialRead the story
Health & function
ACCORD’s intensive glucose target increased mortality and was stopped early
In 10,251 adults with type 2 diabetes and high cardiovascular risk, an intensive multi-drug strategy targeting near-normal glycated hemoglobin did not significantly reduce the primary cardiovascular outcome and increased all-cause mortality.
Human cardiovascular events, mortality and safety · large randomized trialRead the storyHealth & function
A colonoscopy invitation lowered cancer incidence—not mortality at 13 years
In NordICC, inviting adults to one colonoscopy reduced colorectal-cancer incidence at 13 years. Colorectal-cancer mortality was not significantly lower, and participation limits what the invitation result says about completing screening.
Human cancer incidence and mortality · large randomized invitation trialRead the storyHealth & function
Low-dose CT reduced lung-cancer mortality in selected high-risk smokers
NLST found fewer lung-cancer deaths with three annual low-dose CT screens than with chest radiography in selected current and former heavy smokers. The benefit came with many positive results that were false positives under the trial definition.
Human lung-cancer mortality · large randomized screening trialRead the storyHealth & function
PSA screening lowered prostate-cancer mortality—and increased diagnoses
After 21 years in Rotterdam’s ERSPC section, repeated PSA-based screening reduced prostate-cancer mortality and metastatic disease in the primary age group, while producing substantially more prostate-cancer diagnoses.
Human prostate-cancer mortality and diagnosis · long randomized screening follow-upRead the storyDrugs & supplements
Spermidine did not improve the trial’s primary memory outcome
In the 12-month SmartAge trial, a wheat-germ spermidine extract did not improve the prespecified memory outcome or secondary outcomes. Exploratory signals do not establish dementia prevention or longer life.
Human cognitive tests · randomized phase 2b trialRead the storyDrugs & supplements
Urolithin A missed both primary outcomes in older adults
ENERGIZE found no significant benefit for six-minute walk distance or maximal ATP production. Secondary endurance and biomarker signals remain preliminary and do not establish disability prevention or longer healthy life.
Human function and biomarkers · small randomized trialRead the storyDrugs & supplements
GlyNAC’s small trial cannot establish reversal of aging
A 16-week study randomized 24 older adults—12 per arm—and reported many biomarker and function measures. Its size, multiplicity and exploratory analyses do not prove that GlyNAC reverses aging or extends healthspan.
Human biomarkers and function · very small randomized trialRead the story
Everyday foundations
Sauna use was associated with lower mortality—not proven to extend life
One Finnish male cohort linked frequent sauna use with lower mortality. The design cannot show that sauna caused longer life, and randomized evidence has not tested that endpoint.
Human mortality association · prospective cohortRead the story
Measuring aging
Cold-water studies measure thermogenesis—not longer life
A small study of young male winter swimmers found physiology differences. It did not test disease, function, healthspan or lifespan, and it cannot show that cold exposure caused the findings.
Human physiology biomarkers · small cross-sectional studyRead the story
Measuring aging
Hyperbaric oxygen changed selected blood-cell markers—not aging itself
A small uncontrolled study reported telomere and senescent-cell changes in selected blood-cell subtypes. It did not test clinical aging, healthspan or lifespan, and commercial conflicts matter.
Human blood-cell biomarkers · uncontrolled pre/post studyRead the storyDrugs & supplements
ASPREE found no gain in disability-free survival—and more major bleeding
In 19,114 selected older adults, aspirin did not improve the death, dementia or persistent-disability composite. Major hemorrhage was higher.
Human function and safety · large randomized trialRead the storyDrugs & supplements
ASPREE did not lower cardiovascular events—and increased major bleeding
The cardiovascular composite was not significantly lower with aspirin, while major hemorrhage occurred more often.
Human cardiovascular and safety outcomes · large randomized trialRead the storyDrugs & supplements
ASPREE’s cancer signal changed across longer follow-up
An unexpected randomized-period cancer-mortality imbalance did not persist as a post-trial legacy association.
Human mortality and cancer outcomes · trial plus observational extensionRead the storyHealth & function
TRAVERSE found cardiovascular noninferiority—not a longevity benefit
Among selected men with hypogonadism and elevated cardiovascular risk, testosterone gel was noninferior to placebo for major cardiovascular events; the trial did not test longer life or general anti-aging use.
Human cardiovascular outcomes · large randomized noninferiority trialRead the storyHealth & function
Testosterone did not prevent fractures in TRAVERSE
Clinical fractures were more frequent with testosterone than placebo in TRAVERSE; a smaller substudy’s bone-density gain cannot substitute for fracture outcomes.
Human fracture and bone-density outcomes · randomized trialsRead the storyHealth & function
Testosterone’s walking result was modest—not an anti-aging effect
The prespecified Physical Function Trial threshold was not significant in its enrolled subgroup; broader secondary walking results do not establish disability prevention, healthspan or longevity.
Human physical-function outcomes · one-year randomized trialsRead the story
Everyday foundations
CBT-I improves later-life insomnia—not aging itself
Two randomized trials support meaningful sleep improvement in older adults; they did not test dementia prevention, biological aging or lifespan.
Human sleep outcomes · randomized behavioral trialsRead the story
Health & function
CPAP improved symptoms—not cardiovascular events in major trials
SAVE and ISAACC did not significantly reduce their primary cardiovascular outcomes; SAVE separately found symptom and quality-of-life benefits.
Human cardiovascular and symptom outcomes · large randomized trialsRead the story
Drugs & supplements
Melatonin can shift sleep outcomes—not human aging
Specific prolonged-release melatonin trials reported modest sleep benefits; they did not test biological-age reversal, healthspan or lifespan.
Human sleep outcomes · product-specific randomized trialsRead the storyHealth & function
Shingles vaccines prevent shingles. Dementia evidence remains non-randomized
Randomized trials established shingles prevention. Dementia findings come from observational and quasi-experimental studies and do not prove prevention.
Human disease outcomes · randomized and non-randomized evidenceRead the storyHealth & function
High-dose flu vaccine reduced influenza—not immune aging
The randomized result was 1.4% versus 1.9% influenza across two seasons, not proof of immune rejuvenation or longer life.
Human infection outcome · large randomized trialRead the storyHealth & function
RSV vaccines reduce respiratory disease. Separate trials cannot rank them
Arexvy, Abrysvo and mResvia each reduced a trial-defined RSV respiratory endpoint, but separate protocols cannot establish a product ranking.
Human respiratory outcomes · three randomized vaccine trialsRead the storyHealth & function
Menopausal hormone therapy treats symptoms. WHI did not show a longevity benefit
WHI found a formulation-specific mix of benefits and harms, no overall 18-year mortality difference, and no basis for general longevity prevention.
Human disease outcomes and mortality · randomized trialsRead the storyHealth & function
Zoledronic acid reduced fractures in osteoporosis—not aging itself
HORIZON reduced vertebral and hip fractures in postmenopausal osteoporosis, with outcome-specific duration and safety limits—not evidence of slower aging.
Human fracture outcomes · large randomized trialRead the storyEveryday foundations
LIFTMOR improved bone density in a small supervised trial—not fracture prevention
LIFTMOR found BMD and function gains in a small, screened, closely supervised trial—not fracture prevention or proof that unsupervised heavy training is safe.
Human BMD and function · small supervised randomized trialRead the story
Health & function
FINGER slightly improved cognitive-test scores. It did not prove dementia prevention
A combined two-year program produced a small cognitive-test advantage; it cannot identify a winning component or establish dementia, disability, mortality, healthspan, or lifespan benefit.
Human cognitive tests · randomized multidomain trialRead the story
Everyday foundations
The MIND diet trial found no cognitive edge over its active control
Both groups improved with counseling and calorie restriction; the between-group cognitive difference was not significant and MRI measures were similar.
Human cognition and MRI · randomized dietary trialRead the story
Health & function
Cognitive training improved practiced skills—not survival or proven dementia prevention
ACTIVE supports trained-ability gains and some function signals, found no mortality benefit, and leaves a claims-based dementia subgroup methodologically disputed.
Human trained abilities and long-term outcomes · randomized trial plus disputed secondary analysisRead the storyDrugs & supplements
Vitamin D is essential. VITAL still found no broad prevention benefit
In generally healthy adults, vitamin D3 did not significantly reduce invasive cancer, major cardiovascular events, or fractures; deficiency treatment is a different question.
Human clinical outcomes · large randomized prevention trialRead the storyHealth & function
Multivitamins moved some tests and aging clocks. What does that mean?
COSMOS found small cognitive-test differences and modest movement in two DNA-methylation clocks; neither establishes dementia prevention or longer life.
Human cognitive tests and biomarkers · correlated randomized substudiesRead the storyDrugs & supplements
Resveratrol has a longevity reputation. Human trials tell a mixed story
One small memory-test signal sits beside several null or unfavorable metabolic trials; human evidence does not show longer life or healthspan.
Human biomarkers and cognitive tests · small heterogeneous trialsRead the storyHealth & function
SPRINT reduced cardiovascular events—not aging itself
Intensive treatment lowered cardiovascular events and mortality in eligible high-risk adults, with more hypotension, electrolyte problems and kidney injury.
Human clinical outcomes · large randomized trialRead the storyDrugs & supplements
Statin evidence changes with age, risk and prevention setting
Evidence is clearer after vascular disease than for starting primary prevention after age 75, and it does not establish longer life.
Human clinical outcomes · trials and pooled evidenceRead the storyDrugs & supplements
“Omega-3” is not one intervention—and the trial results do not transfer
Two mixed EPA+DHA trials were neutral on primary outcomes; prescription icosapent ethyl benefited a defined high-risk population with safety and comparator limits.
Human clinical outcomes · formulation-specific randomized trialsRead the storyHealth & function
Hearing intervention did not slow cognitive decline across the full ACHIEVE trial
The three-year trial was null across its full cohort. Signals in higher-risk groups need confirmation and do not establish dementia prevention.
Human outcomes · randomized trial with subgroup signalsRead the storyEveryday foundations
Human time-restricted-eating trials show mixed short-term results—not slower aging
Different eating windows and comparators produced different weight and fat findings; none tested biological aging, healthspan or lifespan.
Human outcomes · short randomized trialsRead the storyDrugs & supplements
Creatine added to resistance training may improve some strength measures—not longevity
Pooled short trials found modest lean-mass and strength gains, while a related one-year analysis found no additional benefit.
Human function · trials and pooled evidenceRead the storyEveryday foundations
Structured physical activity reduced late-life mobility disability—not aging itself
LIFE supports a meaningful mobility outcome in vulnerable older adults, while lifespan and universal-program claims remain untested.
Human function · randomized trialsRead the storyDrugs & supplements
Semaglutide reduced cardiovascular events in SELECT—not aging
The randomized result and approved indication are population-specific; anti-aging, healthspan and lifespan claims were not tested.
Human clinical outcomes · large randomized trialRead the storyDrugs & supplements
NAD precursors raise some metabolites; human longevity benefits remain unproven
Small trials show target engagement, not broad clinical, healthspan or lifespan benefit—and products and routes are not interchangeable.
Human biomarkers · small trialsRead the storyEveryday foundations
Sleep patterns are linked to healthy aging—but most evidence is observational
Duration, regularity and fragmentation carry health signals, but the featured studies do not show that changing one metric extends lifespan.
Human outcomes · mostly observational evidenceRead the storyEveryday foundations
PREDIMED found fewer cardiovascular events after a Mediterranean-style diet—with a correction history
The corrected randomized analysis is promising for its composite endpoint, while allocation deviations and lifespan limits remain visible.
Human clinical outcomes · corrected randomized trialRead the storyDrugs & supplements
Metformin is established for diabetes—not for extending healthy human life
Small older-adult studies show mechanistic changes and a blunted hypertrophy signal, not healthspan or lifespan extension.
Human biomarkers and muscle · small trialsRead the storyEveryday foundations
CALERIE tested calorie restriction for two years—not human lifespan
A randomized trial found selected cardiometabolic improvements, while aging-biomarker results were mixed and lifespan was not measured.
Human outcomes and biomarkers · randomized trialRead the storyDrugs & supplements
Human senolytic studies remain small safety and feasibility pilots
Three disease-specific pilot studies do not establish rejuvenation, healthy-person benefit, healthspan or lifespan extension.
Early human safety and feasibility · small pilotsRead the storyMeasuring aging
What an epigenetic clock can—and cannot—tell you
Different clocks target different constructs. A score is not a diagnosis, and changing it does not prove longer life.
Biomarker methods · human validation evidenceRead the storyExperimental biotechnology
Partial-reprogramming trial is testing eye-treatment safety—not human rejuvenation
A recruiting Phase 1 eye study asks whether ER-100 can be administered safely. It has no posted human efficacy results and does not test lifespan.
Early human safety trial · no results yetRead the storyDrugs & supplements
PEARL trial found no change in its main visceral-fat outcome
The 48-week randomized trial reported a null primary outcome, exploratory signals and substantial limits on broader healthy-aging claims.
Human outcomes · small randomized trialRead the storyEveryday foundations
Exercise has strong evidence for function—not proof of slower biological aging
Human trials support mobility and physical function in defined populations. Lifespan and biological-age claims require separate evidence.
Human function · mature randomized evidenceRead the story